These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 3632369)

  • 1. Dietary influences on the antiparkinsonian response to levodopa.
    Juncos JL; Fabbrini G; Mouradian MM; Serrati C; Chase TN
    Arch Neurol; 1987 Oct; 44(10):1003-5. PubMed ID: 3632369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma levels of amino acids correlate with motor fluctuations in parkinsonism.
    Pincus JH; Barry KM
    Arch Neurol; 1987 Oct; 44(10):1006-9. PubMed ID: 3632370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amount and distribution of dietary protein affects clinical response to levodopa in Parkinson's disease.
    Carter JH; Nutt JG; Woodward WR; Hatcher LF; Trotman TL
    Neurology; 1989 Apr; 39(4):552-6. PubMed ID: 2648188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dietary method for reducing fluctuations in Parkinson's disease.
    Pincus JH; Barry KM
    Yale J Biol Med; 1987; 60(2):133-7. PubMed ID: 3577210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism.
    Nutt JG; Woodward WR; Anderson JL
    Ann Neurol; 1985 Nov; 18(5):537-43. PubMed ID: 4073849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease.
    Hauser RA; Ellenbogen AL; Metman LV; Hsu A; O'Connell MJ; Modi NB; Yao HM; Kell SH; Gupta SK
    Mov Disord; 2011 Oct; 26(12):2246-52. PubMed ID: 21755537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlled-release levodopa/carbidopa. I. Sinemet CR3 treatment of response fluctuations in Parkinson's disease.
    Cedarbaum JM; Breck L; Kutt H; McDowell FH
    Neurology; 1987 Feb; 37(2):233-41. PubMed ID: 3808304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exercise and the antiparkinsonian response to levodopa.
    Mouradian MM; Juncos JL; Serrati C; Fabbrini G; Palmeri S; Chase TN
    Clin Neuropharmacol; 1987 Aug; 10(4):351-5. PubMed ID: 3503678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Controlled-release levodopa/carbidopa. II. Sinemet CR4 treatment of response fluctuations in Parkinson's disease.
    Cedarbaum JM; Breck L; Kutt H; McDowell FH
    Neurology; 1987 Oct; 37(10):1607-12. PubMed ID: 3658164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of a controlled low-protein diet on the pharmacological response to levodopa and on the plasma levels of L-dopa and amino acids in patients with Parkinson's disease].
    Sanchís G; Mena MA; Martín del Río R; Morales B; Casarejo MJ; de Yébenes MJ; Tabernero C; Jiménez A; de Yébenes JG
    Arch Neurobiol (Madr); 1991; 54(6):296-302. PubMed ID: 1811460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Central levodopa influx and the clinical motor response to levodopa in patients with Parkinson disease complicated with motor fluctuations and dyskinesias.
    López-Ariztegui N; Arévalo MA; de Ceballos ML; Grandas F
    Clin Neuropharmacol; 2009; 32(6):321-5. PubMed ID: 19667975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral levodopa/carbidopa solution versus tablets in Parkinson's patients with severe fluctuations: a pilot study.
    Kurth MC; Tetrud JW; Irwin I; Lyness WH; Langston JW
    Neurology; 1993 May; 43(5):1036-9. PubMed ID: 8492922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The effect of controlled release of DOPA and carbidopa on clinical response and plasma pharmacokinetics of DOPA in parkinsonian patients].
    García de Yébenes J; Mateo D; Pino MA; Cordero M; Pastor M; Chacón J; Morales B; Sánchez V; Mena MA; Giménez Roldán S
    Neurologia; 1997 Apr; 12(4):145-56. PubMed ID: 9235023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controlled release levodopa treatment of motor fluctuations in Parkinson's disease.
    Juncos JL; Fabbrini G; Mouradian MM; Serrati C; Kask AM; Chase TN
    J Neurol Neurosurg Psychiatry; 1987 Feb; 50(2):194-8. PubMed ID: 3572434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease.
    Nutt JG; Carter JH; Lea ES; Woodward WR
    Mov Disord; 1997 May; 12(3):285-92. PubMed ID: 9159720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlled-release carbidopa/levodopa (CR) in parkinsonian patients with response fluctuations on standard levodopa treatment: clinical and pharmacokinetic observations.
    Deleu D; Jacques M; Michotte Y; Ebinger G
    Neurology; 1989 Nov; 39(11 Suppl 2):88-92; discussion 95. PubMed ID: 2685654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levodopa with benserazide or carbidopa in Parkinson disease.
    Rinne UK; Mölsä P
    Neurology; 1979 Dec; 29(12):1584-9. PubMed ID: 574221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levodopa and 3-O-methyldopa plasma levels in parkinsonian patients with stable and fluctuating motor response.
    Luquin MR; Vaamonde J; Obeso JA
    Clin Neuropharmacol; 1989 Feb; 12(1):46-54. PubMed ID: 2713867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A balanced carbohydrate: protein diet in the management of Parkinson's disease.
    Berry EM; Growdon JH; Wurtman JJ; Caballero B; Wurtman RJ
    Neurology; 1991 Aug; 41(8):1295-7. PubMed ID: 1866021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Observational Study of the Effect of Levodopa-Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson's Disease Patients.
    Krüger R; Lingor P; Doskas T; Henselmans JML; Danielsen EH; de Fabregues O; Stefani A; Sensken SC; Parra JC; Onuk K; Yegin A; Antonini A
    Adv Ther; 2017 Jul; 34(7):1741-1752. PubMed ID: 28631218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.